Abstract
Gfi-1 is a nuclear zinc finger protein with the activity of a transcriptional repressor and the ability to predispose for the development of T-cell lymphoma when expressed constitutively at high levels. Whereas thymic T-cell precursors express endogenous Gfi-1, mature peripheral T-cells lack Gfi-1 but upregulate its expression transiently after antigenic stimulation and activation of Erk1/2 demonstrating a role of Gfi-1 in T-cell activation. Here we show that constitutive expression of Gfi-1 accelerates S phase entry of primary, resting T-cells upon antigenic stimulation. In addition, high level Gfi-1 expression inhibits phorbol ester induced G1 arrest and activation induced cell death in Jurkat T-cells. We demonstrate that these effects of Gfi-1 concur with lower absolute levels and hyperphosphorylation of the pocket protein pRb. Moreover, phorbol ester induced expression of the negative cell cycle regulator p21WAF1 is blocked in the presence of Gfi-1. These findings suggest that Gfi-1 contributes to T-cell lymphomagenesis by overriding a late G1 cell cycle checkpoint which controls activation induced death and S phase entry of T-cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Brehm A, Miska E, Reid J, Bannister A, Kouzarides T . 1999 Br. J. Cancer 80: 38–41
Firpo EJ, Koff A, Solomon MJ, Roberts JM . 1994 Mol. Cell. Biol. 14: 4889–4901
Gilks CB, Bear SE, Grimes HL, Tsichlis PN . 1993 Mol. Cell. Biol. 13: 1759–1768
Green DR, Scott DW . 1994 Curr. Opin. Immunol. 6: 476–487
Grimes HL, Chan TO, Zweidler-McKay PA, Tong B, Tsichlis PN . 1996 Mol. Cell. Biol. 16: 6263–6272
Harbour JW, Dean DC . 2000 Genes Dev. 14: 2393–2409
Jones LA, Chin LT, Longo DL, Kruisbeek AM . 1990 Science 250: 1726–1729
Kabelitz D, Pohl T, Pechhold K . 1993 Immunol. Today 14: 338–339
Karas M, Zaks TZ, Liu JL, LeRoith D . 1999 Mol. Cell. Biol. 10: 4441–4450
Karsunky H, Geisen C, Schmidt T, Haas K, Zevnik B, Gau E, Möröy T . 1999 Oncogene, 18: 7816–7824
Lenardo MJ, Boehme S, Chen L, Combadiere B, Fisher G, Freedman M, McFarland H, Pelfrey C, Zheng L . 1995 Int. Rev. Immunol. 13: 115–134
Li QS, Tanaka S, Kisenge RR, Toyoda H, Azuma E, Komada Y . 2000 Eur. J. Immunol. 30: 3329–3337
Lissy NA, van Dyk LF, Becker-Hapak M, Vocero-Akbani A, Mendler JA, Dowdy SF . 1999 Immunity 8: 57–65
Liu S, Cowell JK . 2000 Ann. Hum. Genet. 64: 83–86
Macian F, Lopez-Rodriguez C, Rao A . 2001 Oncogene 20: 2476–2489
Muller H, Helin K . 2000 Biochim. Biophys. Acta. 1470: M1–M12
Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM . 1994 Nature 372: 570–573
Rocha B, von Boehmer H . 1991 Science 251: 1225–1228
Rödel B, Tavassoli K, Karsunky H, Schmidt T, Bachmann M, Shaper F, Heinrich P, Shuai K, Elsässer HP, Möröy T . 2000 EMBO J. 19: 5845–5855
Scheijen B, Jonkers J, Acton D, Berns A . 1997 J. Virol. 71: 9–16
Schmidt T, Zörnig M, Beneke R, Möröy T . 1996 Nucl. Acids Res. 24: 2528–2534
Schmidt T, Karsunky H, Gau E, Zevnik B, Elsässer HP, Möröy T . 1998 Oncogene 17: 2661–2667
Stankunas K, Graef IA, Neilson JR, Park SH, Crabtree GR . 1999 Cold Spring Harb. Symp. Quant. Biol. 64: 505–516
Wells AD, Gudmundsdottir H, Turka CA . 1997 J. Clin. Invest. 100: 3173–3183
Ziegler SF, Ramsdell F, Alderson MR . 1994 Stem Cells 12: 456–465
Zörnig M, Schmidt T, Karsunky H, Grzeschiczek A, Möröy T . 1996 Oncogene 12: 1789–1801
Zweidler-McKay PA, Grimes HL, Flubacher MM, Tsichlis PN . 1996 Mol. Cell Biol. 16: 4024–4034
Acknowledgements
This work was supported by the Deutsche Forschungsgemeinschaft (grant Mo 435/9-1, 9-3), the ‘Fonds der chemischen Industrie’, by the European Community Framework 5 Program and the ‘IFORES Program’ of the University of Essen Medical School.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Karsunky, H., Mende, I., Schmidt, T. et al. High levels of the onco-protein Gfi-1 accelerate T-cell proliferation and inhibit activation induced T-cell death in Jurkat T-cells. Oncogene 21, 1571–1579 (2002). https://doi.org/10.1038/sj.onc.1205216
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205216
Keywords
This article is cited by
-
A novel regulatory circuit between p53 and GFI1 controls induction of apoptosis in T cells
Scientific Reports (2019)
-
Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis
Journal of Hematology & Oncology (2018)
-
Prognostic significance of high GFI1 expression in AML of normal karyotype and its association with a FLT3-ITD signature
Scientific Reports (2017)
-
Gfi1Cre mice have early onset progressive hearing loss and induce recombination in numerous inner ear non-hair cells
Scientific Reports (2017)
-
GFI1 as a novel prognostic and therapeutic factor for AML/MDS
Leukemia (2016)